Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15657177
Zheng Y, et al. (2005) Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105, 3648-54 15657177
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go_6976 anti-IgM inhibit treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go_6976 anti-CD3 inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go_6976 anti-IgM inhibit treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go_6976 anti-CD3 inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go_6976 anti-IgM inhibit treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go_6976 anti-CD3 inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go_6976 anti-IgM inhibit treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go_6976 anti-CD3 inhibit treatment-induced increase

T184-p - RASGRP1 (human)
Modsite: RDWSRKLtQRIKSNT SwissProt Entrez-Gene
Orthologous residues
RASGRP1 (human): T184‑p, RASGRP1 (mouse): T184‑p, RASGRP1 (rat): T184‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-CD3 increase
Ro31-8220 anti-CD3 inhibit treatment-induced increase
Go_6976 anti-CD3 inhibit treatment-induced increase
phorbol_ester increase

T133-p - RASGRP3 (human)
Modsite: YDWMRRVtQRKKVSK SwissProt Entrez-Gene
Orthologous residues
RASGRP3 (human): T133‑p, RASGRP3 iso2 (human): T133‑p, RASGRP3 (mouse): T133‑p, RASGRP3 (rat): T133‑p, RASGRP3 (chicken): T133‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte), Rat2 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCD (human)
KINASE PKCT (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCT (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anti-IgM increase
Ro31-8220 anti-IgM inhibit treatment-induced increase
Go_6976 anti-IgM inhibit treatment-induced increase
phorbol_ester increase
Ro31-8220 phorbol_ester inhibit treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase